专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06994977B2 Method of identifying inhibitors of C—C chemokine receptor 3 失效
公开(公告)号：US06994977B2
公开(公告)日：2006-02-07
申请号：US10283028
申请日：2002-10-28
申请人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
发明人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
IPC分类号： G01N33/53 , G01N33/566
CPC分类号： C07K16/2866 , A01K2217/05 , A61K38/00 , A61K47/642 , C07K14/7158 , C07K2317/76 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.

2. 发明授权

US06537764B1 Method of identifying inhibitors of C—C chemokine receptor 3 失效
标题翻译：鉴定C-C趋化因子受体3抑制剂的方法
公开(公告)号：US06537764B1
公开(公告)日：2003-03-25
申请号：US08720565
申请日：1996-09-30
申请人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
发明人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
IPC分类号： G01N3353
CPC分类号： C07K16/2866 , A01K2217/05 , A61K38/00 , A61K47/642 , C07K14/7158 , C07K2317/76 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.
摘要翻译：本发明涉及鉴定哺乳动物（例如人）CC趋化因子受体3（CCR3）的抑制剂的方法，其包括将（a）待测化合物，（b）表达重组蛋白的宿主细胞组合，所述重组蛋白包含哺乳动物CCR3和（c）所述受体的配体，在适合于配体与所述受体结合的条件下，以及检测或测量受体 - 配体复合物的形成。化合物对复合物形成的抑制表明化合物是抑制剂。

3. 发明授权

US06806061B1 G protein-coupled receptor gene and methods of use therefor 失效
标题翻译： G蛋白偶联受体基因及其使用方法
公开(公告)号：US06806061B1
公开(公告)日：2004-10-19
申请号：US08375199
申请日：1995-01-19
申请人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
发明人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
IPC分类号： C12N1512
CPC分类号： C07K16/2866 , A01K2217/05 , A61K38/00 , A61K47/642 , C07K14/7158 , C07K2317/76 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C-C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof, and to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides.
摘要翻译：本发明涉及编码称为CC趋化因子受体3（CKR-3）或Eos L2的哺乳动物（例如，人）受体蛋白以及本文称为分离的重组体的蛋白质或多肽的分离和/或重组核酸哺乳动物CKR-3受体。本发明还涉及重组核酸构建体，其包含编码本发明的受体蛋白或其一部分的核酸，以及宿主包含用于产生重组CKR-3受体或多肽的构建体的细胞。

4. 发明授权

US07402657B2 C-C chemokine receptor 3 proteins 失效
标题翻译： C-C趋化因子受体3蛋白
公开(公告)号：US07402657B2
公开(公告)日：2008-07-22
申请号：US11216610
申请日：2005-08-31
申请人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
发明人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
IPC分类号： C07K14/435 , C07K14/52 , A61K38/17
CPC分类号： C07K16/2866 , A01K2217/05 , A61K38/00 , A61K47/642 , C07K14/7158 , C07K2317/76 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to isolated and/or recombinant C-C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides.
摘要翻译：本发明涉及分离的和/或重组的C-C趋化因子受体3（CKR-3，CCR3）蛋白或多肽。

5. 发明授权

US07012133B1 Antibodies to C-C chemokine Receptor 3 Protein 失效
标题翻译： C-C趋化因子受体3蛋白的抗体
公开(公告)号：US07012133B1
公开(公告)日：2006-03-14
申请号：US08963656
申请日：1997-11-03
申请人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
发明人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
IPC分类号： C07K16/00 , C12N15/63 , C12N15/00
CPC分类号： C07K16/2866 , A01K2217/05 , A61K38/00 , A61K47/642 , C07K14/7158 , C07K2317/76 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. Administration of a compound which inhibits or promotes receptor function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.
摘要翻译：本发明涉及编码称为CC趋化因子受体3（CKR-3）或Eos L2的哺乳动物（例如，人）受体蛋白以及本文称为分离的重组体的蛋白质或多肽的分离和/或重组核酸哺乳动物CKR-3受体。本发明还涉及重组核酸构建体，其包含编码本发明的受体蛋白或其部分的核酸; 包含可用于产生重组CKR-3受体或多肽的包含此类构建体的宿主细胞; 以及与受体反应的抗体，其可用于研究和诊断应用。还提供了使用核酸，蛋白质和宿主细胞来鉴定受体功能的配体，抑制剂（例如拮抗剂）或启动子（激动剂）的方法。给予需要治疗的个体抑制或促进受体功能的化合物的施用提供了选择性调节白细胞功能的新方法，其可用于多种炎性和自身免疫疾病或用于治疗感染。作为白细胞如嗜酸性粒细胞和淋巴细胞中存在的主要白细胞趋化因子受体，该受体是药物筛选和设计的关键目标。

6. 发明申请

US20100061983A1 Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody 审中-公开
标题翻译：用人cxc趋化因子受体3抗体抑制白细胞的方法
公开(公告)号：US20100061983A1
公开(公告)日：2010-03-11
申请号：US11903330
申请日：2007-09-21
申请人： Marcel Loetscher , Bernhard Moser , Shixin Qin , Charles R. Mackay
发明人： Marcel Loetscher , Bernhard Moser , Shixin Qin , Charles R. Mackay
IPC分类号： A61K39/395 , C07H21/02 , G01N33/53
CPC分类号： C07K14/7158 , A61K38/00 , A61K47/642
摘要： The present invention relates to proteins or polypeptides, referred to herein as isolated and/Or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.
摘要翻译：本发明涉及称为CXC趋化因子受体3（CXCR3）及其变体的分离和/或重组哺乳动物（例如人）IP-10 / Mig受体蛋白质的蛋白质或多肽，包括特征在于选择性结合一种或多种趋化因子（例如，IP-10和/或Mig）和/或诱导细胞反应的能力（例如，趋化性，胞吐作用）。可以使用蛋白质或其变体或包含免疫原的宿主细胞产生与CXCR3受体反应的抗体。

7. 发明授权

US06184358B2 IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor 失效
标题翻译：称为CXCR3的IP-10 / Mig受体，抗体，核酸及其用途的方法
公开(公告)号：US06184358B2
公开(公告)日：2001-02-06
申请号：US08829839
申请日：1997-03-31
申请人： Marcel Loetscher , Bernhard Moser , Shixin Qin , Charles R. Mackay
发明人： Marcel Loetscher , Bernhard Moser , Shixin Qin , Charles R. Mackay
IPC分类号： C07K1600
CPC分类号： C07K14/7158 , A61K38/00 , A61K47/642
摘要： The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen. Another aspect of the invention relates to isolated and/or recombinant nucleic acids encoding a mammalian (e.g., human) CXCR3 protein and variants thereof, including antisense nucleic acid, recombinant nucleic acid constructs, such as plasmids or retroviral vectors, comprising a nucleic acid which encodes a protein of the present invention or variant thereof, and to host cells comprising a nucleic acid or construct, useful in the production of recombinant proteins. Also encompassed are methods of identifying ligands, and inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function, including methods in which host cells comprising a nucleic acid encoding a CXCR3 or variant thereof are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters. Inhibitors and promoters of receptor function can be used to modulate receptor activity, permitting selective inhibition of lymphocyte function, particularly of effector cells such as activated T lymphocytes and NK cells for therapeutic purposes.
摘要翻译：本发明涉及称为CXC趋化因子受体3（CXCR3）及其变体的分离和/或重组哺乳动物（例如，人）IP-10 / Mig受体蛋白质的蛋白质或多肽，包括特征在于选择性结合一种或多种趋化因子（例如，IP-10和/或Mig）和/或诱导细胞反应的能力（例如，趋化性，胞吐作用）。可以使用蛋白质或其变体或与免疫原相同的宿主细胞产生与CXCR3受体反应的抗体。本发明的另一方面涉及编码哺乳动物（例如人）CXCR3蛋白及其变体的分离和/或重组核酸，包括反义核酸，重组核酸构建体，例如质粒或逆转录病毒载体，其包含编码本发明或其变体的蛋白质的核酸，以及宿主细胞，所述宿主细胞包含核酸或构建体，其可用于生产重组蛋白质。还包括鉴定受体功能的配体和抑制剂（例如拮抗剂）或启动子（例如激动剂）的方法，包括其中使用包含编码CXCR3或其变体的核酸的宿主细胞用于鉴定和评估配体，抑制剂或启动子的功效。受体功能的抑制剂和启动子可用于调节受体活性，允许选择性抑制淋巴细胞功能，特别是效应细胞例如活化的T淋巴细胞和NK细胞用于治疗目的。

8. 发明授权

US07407655B2 Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody 失效
标题翻译：用人CXC趋化因子受体3抗体抑制白细胞的方法
公开(公告)号：US07407655B2
公开(公告)日：2008-08-05
申请号：US10251686
申请日：2002-09-20
申请人： Marcel Loetscher , Bernhard Moser , Shixin Qin , Charles R. Mackay
发明人： Marcel Loetscher , Bernhard Moser , Shixin Qin , Charles R. Mackay
IPC分类号： A61K39/395
CPC分类号： C07K14/7158 , A61K38/00 , A61K47/642
摘要： The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.
摘要翻译：本发明涉及称为CXC趋化因子受体3（CXCR3）及其变体的分离和/或重组哺乳动物（例如，人）IP-10 / Mig受体蛋白质的蛋白质或多肽，包括特征在于选择性结合一种或多种趋化因子（例如，IP-10和/或Mig）和/或诱导细胞反应的能力（例如，趋化性，胞吐作用）。可以使用蛋白质或其变体或包含免疫原的宿主细胞产生与CXCR3受体反应的抗体。

9. 发明申请

US20100291579A1 Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses 审中-公开
标题翻译：编码具有预后，诊断，预防，治疗和其他用途的蛋白质的新基因
公开(公告)号：US20100291579A1
公开(公告)日：2010-11-18
申请号：US12803671
申请日：2010-07-01
申请人： Christopher C. Fraser , Sean Anthony McCarthy , John D. Sharp , Thomas M. Barnes , Nicholas C. Wrighton , Charles R. Mackay , Kevin R. Leiby , Douglas A. Holtzman
发明人： Christopher C. Fraser , Sean Anthony McCarthy , John D. Sharp , Thomas M. Barnes , Nicholas C. Wrighton , Charles R. Mackay , Kevin R. Leiby , Douglas A. Holtzman
IPC分类号： C12Q1/68 , G01N33/53 , C12P21/06 , C12N5/10 , C12N5/02 , C12N15/63 , C07K14/435 , C07K16/18 , C07K1/00 , C07H21/04
CPC分类号： C07K16/18
摘要： The invention provides isolated nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供分离的核酸分子和多肽分子。本发明还提供反义核酸分子，含有本发明的核酸分子的表达载体，已经引入了表达载体的宿主细胞和其中引入了本发明的核酸分子的非人转基因动物，或中断了本发明还进一步提供分离的多肽，融合多肽，抗原肽和抗体。还提供利用本发明组合物的诊断，筛选和治疗方法。

10. 发明申请

US20090286956A1 DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof 有权
标题翻译： DELTA3，FTHMA-070，TANGO85，TANGO77，SPOIL，NEOKINE，TANGO129和INTEGRIN ALPHA SUBUNIT蛋白质和核酸分子及其用途
公开(公告)号：US20090286956A1
公开(公告)日：2009-11-19
申请号：US11974478
申请日：2007-10-12
申请人： Sean A. McCarthy , David P. Gearing , Douglas A. Holtzman , Yang Pan , Samantha J. Busfield , Thomas M. Barnes , Charles R. Mackay , Jose M. Lora
发明人： Sean A. McCarthy , David P. Gearing , Douglas A. Holtzman , Yang Pan , Samantha J. Busfield , Thomas M. Barnes , Charles R. Mackay , Jose M. Lora
IPC分类号： C07K14/705
CPC分类号： C12Q1/48 , A61K38/00 , C07K14/47 , C07K2319/00 , C12Q1/6876
摘要： The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供新颖的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259多肽，蛋白质和核酸分子。除了分离的全长Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259蛋白外，本发明还提供了分离的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259融合蛋白质，抗原肽和抗Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259抗体。本发明还提供了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259核酸分子，含有本发明的核酸分子的重组表达载体，已经引入表达载体的宿主细胞，已经引入或破坏了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129或A259基因的人类转基因动物。还提供利用本发明组合物的诊断，筛选和治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式